The generic amyloid formation inhibition effect of a designed small aromatic β-breaking peptide

Amyloid

Volumn 18, Issue 3, 2011, Pages 119-127

  Frydman Marom, Anat ^a   Shaltiel Karyo, Ronit ^a   Moshe, Sari ^a   Gazit, Ehud ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

sheet breaker; Amyloid formation; Aromatic interaction; Inhibition; Self assembly

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID; ALPHA SYNUCLEIN; AMYLIN; AMYLOID; CALCITONIN; DIPEPTIDE; POLYPEPTIDE; TRYPTOPHAN;

ALZHEIMER DISEASE; ARTICLE; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG TARGETING; FLUORESCENCE; HUMAN; MOLECULE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TRANSMISSION ELECTRON MICROSCOPY;

AMINO ACIDS, AROMATIC; AMYLOID BETA-PEPTIDES; BACTERIA; DIPEPTIDES; DRUG DESIGN; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

EID: 80052229078     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2011.582902     Document Type: Article

References (45)

1. Querfurth HW, LaFerla FM. Alzheimers disease. N Engl J Med 2010;362:329-344.
2. Dobson CM. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 2001;356:133-144.
3. Serpell LC. Alzheimers amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000;1:16-30. (Pubitemid 30433852)
4. Gazit E. The role of prefibrillar assemblies in the pathogenesis of amyloid diseases. Drugs Fut 2004;29:613-619. (Pubitemid 39050290)
5. Hoppener JW, Nieuwenhuis MG, Vroom TM, Ahren B, Lips CJ. Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? Mol Cell Endocrinol 2002;197: 205-212. (Pubitemid 35304794)
6. Cascio M, Glazer PA, Wallace BA. The secondary structure of human amyloid deposits as determined by circular dichroism spectroscopy. Biochem Biophys Res Commun 1989;162:1162-1166. (Pubitemid 19214706)
7. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci 2000;9:1960-1967.
8. Blake CC, Serpell LC, Sunde M, Sandgren O, Lundgren E. A molecular model of the amyloid fibril. Ciba Found Symp 1996;199:6-15.
9. Sunde M, Blake CCF. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 1997;50:123-159. (Pubitemid 27449487)
10. Fandrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myoglobin. Nature 2001;410:165-166.
11. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507-511. (Pubitemid 34288846)
12. Selkoe DJ. Folding proteins in fatal ways. Nature 2003;426:900-904. (Pubitemid 38056883)
13. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006;27:570-575. (Pubitemid 43290525)
14. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E. Cognitive-performance recovery of Alzheimers disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl 2009;48:1981-1986.
15. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Casta? EM, Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimers therapy. Nat Med 1998;4:822-826. (Pubitemid 28331024)
16. Gilead S,Gazit,E. Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid. Angew Chem Int Ed Engl 2004;43:4041-4044. (Pubitemid 39257449)
17. Gazit E. A possible role for β-stacking in self-assembly of amyloid fibrils. FASEB J 2002;16:77-83. (Pubitemid 34027953)
18. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM.Prediction of "aggregation-prone" and "aggregation susceptible" regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005;350:379-392. (Pubitemid 40805470)
19. Gazit E. Mechanistic studies of the process of amyloid fibrils formation by the use of peptide fragments and analogues: implications for the design of fibrillization inhibitors. Curr Med Chem 2002;9:1725-1735.
20. Porat Y, Mazor Y, Efrat S, Gazit E. Inhibition of Islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 2004;43:14454-14462. (Pubitemid 39491980)
21. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LCM. Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 2005;102:315-320. (Pubitemid 40116764)
22. Inouye H, Sharma D, Goux WJ, Kirschner DA. Structure of core domain of fibril forming PHF/Tau fragments. Biophys J 2006;90:1774-1789.
23. Platt GW, Routledge KE, Homans SW, Radford SE. Fibril growth kinetics reveal a region of beta2-microglobulin important for nucleation and elongation of aggregation. J Mol Biol 2008;378: 251-263.
24. Bastianetto S, Krantic S, Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimers disease. Mini Rev Med Chem 2008;8:429-435.
25. Lee VM. Amyloid binding ligands as Alzheimers disease therapies. Neurobiol Aging 2002;23:1039-1042. (Pubitemid 35447785)
26. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67:27-37. (Pubitemid 43881385)
27. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15:558-566. (Pubitemid 351799141)
28. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 1994;91:12243-12247. (Pubitemid 24368641)
29. Qin XY, Cheng Y, Cui J, Zhang Y, Yu LC. Potential protection of curcumin against amyloid beta-induced toxicity on cultured rat prefrontal cortical neurons. Neurosci Lett 2009;463:158-161.
30. Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol 2008;115:479-489.
31. Frid P, Anisimov SV, Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev 2007;53:135-160. (Pubitemid 44854214)
32. Rambold AS, Miesbauer M, Olschewski D, Seidel R, Riemer C, Smale L, Brumm L, Levy M, Gazit E, Oesterhelt D, et al. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem 2008;107:218-229.
33. Forno LS. Neuropathology of Parkinsons disease. J Neuropathol Exp Neurol 1996;55:259-272.
34. Reches M, Porat Y, Gazit E. Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J Biol Chem 2002;277:35475-35480.
35. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 2004;53:1509-1516. (Pubitemid 38697663)
36. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 1990;87:5036-5040.
37. Sletten K, Westermark P, Natvig JB. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid. J Exp Med 1976;143:993-998.
38. Volles MJ, Lansbury PT Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 2007;366:1510-1522. (Pubitemid 46215614)
39. Tsigelny IF, Bar-On P, Sharikov Y, Crews L, Hashimoto M, Miller MA, Keller SH, Platoshyn O, Yuan JX, Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J 2007;274:1862-1877. (Pubitemid 46426920)
40. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10 Suppl:S10-S17. (Pubitemid 38901862)
41. Porat Y, Stepensky A, Ding FX, Naider F, Gazit E. Completely different amyloidogenic potential of nearly identical peptide fragments. Biopolymers 2003;69:161-164. (Pubitemid 36693240)
42. Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D. Selection of D-amino-acid peptides that bind to Alzheimers disease amyloid peptide abeta1-42 by mirror image phage display. Chembiochem 2003;4:748-753. (Pubitemid 37010600)
43. Chalifour RJ, McLaughlin RW, Lavoie L, Morissette C, Tremblay N, Boule M, Sarazin P, Stea D, Lacombe D, Tremblay P, et al. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J Biol Chem 2003;278:34874-34881. (Pubitemid 37102246)
44. Esteras-Chopo A, Morra G, Moroni E, Serrano L, Lopez de la Paz M, Colombo G. A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation. J Mol Biol 2008;383:266-280.
45. Karle IL, Balaram P. Structural characteristics of alpha-helical peptide molecules containing Aib residues. Biochemistry 1990;29:6747-6756. (Pubitemid 20225472)